This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Zydus gets India nod to sell 'affordable' cancer drug amid Squibb patent dispute

By Freny Patel ( January 13, 2026, 00:04 GMT | Insight) -- An injunction against Zydus Lifesciences has been lifted by an Indian court, allowing the sale of its cheaper cancer biosimilar despite a Squibb patent dispute. The Delhi High Court cited public interest and lack of claim mapping.In a major win for the Indian pharmaceutical industry and access to affordable healthcare, an Indian court has lifted an injunction against Zydus Lifesciences, clearing the way for the domestic drugmaker to market its biosimilar version of the anti-cancer drug Nivolumab. ...

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login